Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082070 | 1.00 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL5173645 | 0.86 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7076273 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7076274 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7076771 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7079285 | 0.84 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7080262 | 0.83 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7080259 | 0.83 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7080359 | 0.82 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CHRNA7 | |
| SCHEMBL7080361 | 0.82 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | claimed |
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | disclosed |
| WO-2002083622-A2 | NOVEL AMINOPHENYL KETONE DERIVATIVES | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | MAPKAPK2, MAP3K2, MAP3K1 | MAPK14 28/4885MAPK13 33/4885MAPK12 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.